Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 11/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.47 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.47 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.47 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.47 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.47 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.47 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.47 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.47 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.47 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.47 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.47 |
| ▸ | PSMB3 | P49720 | 3/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.47 |
| ▸ | PSMA6 | P60900 | 3/20 | 0.47 |
| ▸ | PSMA8 | Q8TAA3 | 3/20 | 0.47 |
| ▸ | PSMB7 | Q99436 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370283 | 1.00 | PSMB5 (0.50) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL28448248 | 0.88 | ITGB2 (0.55) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL22370519 | 0.86 | PSMB5 (0.49) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL22370518 | 0.86 | PSMB5 (0.49) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL22370835 | 0.84 | MEN1 (0.51) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL22370833 | 0.84 | MEN1 (0.51) | PSMB5PYGLPSMB8PSMB11PSMA7 | |
| SCHEMBL3975886 | 0.79 | HDAC1 (0.53) | PSMB5PYGLALDH1A1NOS2TACR3 | |
| SCHEMBL3975891 | 0.79 | HDAC1 (0.53) | PSMB5PYGLALDH1A1NOS2TACR3 | |
| SCHEMBL30272391 | 0.79 | PYGL (0.61) | PSMB5PYGLALDH1A1NOS2TACR3 | |
| SCHEMBL28607015 | 0.78 | PYGL (0.63) | PSMB5PYGLALDH1A1NOS2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | PSMB5 15/4885PYGL 4319/4885PSMB8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.